Curriculum Vitae
Research
Interest
HDL cholesterol and metabolism.
Representative
Publications
Ansell BJ. Rationale for
combination therapy with statins in the treatment of
dyslipidemia. Current Atherosclerosis Reports. 2005;7:29-33.
Davidson MH, Maki KC, Pearson TA,
Pasternak RC, Deedwania PC, McKenney JM, Fonarow GC, Maron DJ,
Ansell BJ, Clark LT, Stone NJ, Ballantyne CM. Results of the
National Cholesterol Education Program Evaluation Project
Utilizing Novel E-Technology (NEPTUNE) II Survey: Implications
for Treatment Under the Revised Adult Treatment Panel III
Guidelines. American Journal of Cardiology. 2005;95-556-563.
Navab M, Anantharamaiah GM, Reddy
ST, Van Lenten BJ, Ansell BJ, Hama S, Hough G, Grijalva VR,
Kamranpour N, Wagner AC, Mehrabian M, Shaposhnik Z, Lusis AJ,
and Fogelman AM. The double jeopardy of HDL. Annals of
Medicine. 2005;37:173-78.
Navab M, Anantharamaiah GM, Reddy
ST, Hama S, Hough G, Grijalva VR, Yu N, Ansell BJ, Datta G,
Garber DW, Fogelman AM. Apolipoprotein A-I Mimetic Peptides.
Arteriosclerosis, Thrombosis, and Vascular Biology.
2005;25:1-7.
Ansell BJ. Evidence for a combined
approach to the management of hypertension and dyslipidemia.
American Journal of Hypertension. 2005;18;1249-57.
Ansell BJ, Navab M, Watson KE,
Fogelman, AM, Fonarow GC. HDL: Recent Advances. Journal of the
American College of Cardiology. 2005;46:1792-98.
Ansell BJ. C-Reactive Protein Not
a Reliable Marker for CV Risk in the Elderly. Reply to letter
to Editor. Resident & Staff Physician. 2006;52:7.
Ansell BJ. How to get your
high-risk patients to the new NCEP goals. Patient Care.
2006;40;26-34.
Ansell BJ, Fonarow GC, Fogelman
AM. HDL: Is it always atheroprotective? Current Athersclerosis
Reports. 2006;8:405-11.
Navab MN, Ansell BJ, Fogelman AM.
Mechanisms of disease: proatherogenic HDL – an evolving field.
Nature Clinical Practice: Endocrinology and Metabolism.
2006;2;1-8.
|
